What is the current valuation of the UK Dry Age Related Macular Degeneration AMD market?

The market valuation was 199.92 USD Million in 2024. Read More

What is the projected market size for the UK Dry AMD market by 2035?

The projected valuation for the UK Dry AMD market is 443.94 USD Million by 2035. Read More

What is the expected CAGR for the UK Dry AMD market during the forecast period?

The expected CAGR for the UK Dry AMD market from 2025 to 2035 is 7.52%. Read More

Which companies are the key players in the UK Dry AMD market?

Key players include Novartis AG, Regeneron Pharmaceuticals Inc, Roche Holding AG, Bayer AG, Allergan PLC, Apellis Pharmaceuticals Inc, Santen Pharmaceutical Co Ltd, and Zeiss Group. Read More

How is the UK Dry AMD market segmented by disease stage?

The market is segmented into Early Stage (59.97 to 135.0 USD Million), Intermediate Stage (79.96 to 180.0 USD Million), and Late Stage (59.99 to 128.94 USD Million). Read More

What are the treatment types available in the UK Dry AMD market?

Treatment types include Pharmacological Treatment (80.0 to 180.0 USD Million), Surgical Intervention (50.0 to 120.0 USD Million), and Nutritional Supplements (69.92 to 143.94 USD Million). Read More

How does patient demographics affect the UK Dry AMD market?

The market segments by patient demographics include Age Group (50.0 to 110.0 USD Million), Gender (60.0 to 130.0 USD Million), and Socioeconomic Status (89.92 to 203.94 USD Million). Read More

What healthcare settings are involved in the UK Dry AMD market?

Healthcare settings include Outpatient Clinics (40.0 to 90.0 USD Million), Hospitals (70.0 to 160.0 USD Million), and Home Healthcare (89.92 to 193.94 USD Million). Read More

What are the distribution channels for the UK Dry AMD market?

The market distribution channels consist of Direct Sales (79.96 to 179.94 USD Million), Online Sales (59.97 to 134.96 USD Million), and Pharmacies (59.99 to 129.04 USD Million). Read More

What trends are expected in the UK Dry AMD market by 2035?

The market is likely to experience growth driven by advancements in treatment options and increasing patient awareness, with a projected valuation of 443.94 USD Million. Read More

UK Dry Age Related Macular Degeneration Market

ID: MRFR/MED/43214-HCR

200 Pages

Vikita Thakur

Last Updated: April 06, 2026

UK Dry Age-Related Macular Degeneration (AMD) Market Research Report: Size, Share, Trend Analysis By Stage (early age-related macular degeneration, intermediate age-related macular degeneration, late age-related macular degeneration), By Age Group (above 75 years, above 60 years, above 40 years), By Diagnosis and Treatment (treatment, diagnosis), By Route of Administration (oral, injectables) and By End Userss (hospitals clinics, diagnostic centers, academic research institutes) - Growth Outlook & Industry Forecast 2025 To 2035

UK Dry Age Related Macular Degeneration Market Infographic

Summary Table of Contents Segmentation Download PDF

Certified Researchers

Customize Report

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. 1.1 EXECUTIVE SUMMARY
  1. 1.1.1 Market Overview
  2. 1.1.2 Key Findings
  3. 1.1.3 Market Segmentation
  4. 1.1.4 Competitive Landscape
  5. 1.1.5 Challenges and Opportunities
  6. 1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
1. 2.1 MARKET INTRODUCTION
  1. 2.1.1 Definition
  2. 2.1.2 Scope of the study
    1. 2.1.2.1 Research Objective
    2. 2.1.2.2 Assumption
    3. 2.1.2.3 Limitations
2. 2.2 RESEARCH METHODOLOGY
  1. 2.2.1 Overview
  2. 2.2.2 Data Mining
  3. 2.2.3 Secondary Research
  4. 2.2.4 Primary Research
    1. 2.2.4.1 Primary Interviews and Information Gathering Process
    2. 2.2.4.2 Breakdown of Primary Respondents
  5. 2.2.5 Forecasting Model
  6. 2.2.6 Market Size Estimation
    1. 2.2.6.1 Bottom-Up Approach
    2. 2.2.6.2 Top-Down Approach
  7. 2.2.7 Data Triangulation
  8. 2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
1. 3.1 MARKET DYNAMICS
  1. 3.1.1 Overview
  2. 3.1.2 Drivers
  3. 3.1.3 Restraints
  4. 3.1.4 Opportunities
2. 3.2 MARKET FACTOR ANALYSIS
  1. 3.2.1 Value chain Analysis
  2. 3.2.2 Porter's Five Forces Analysis
    1. 3.2.2.1 Bargaining Power of Suppliers
    2. 3.2.2.2 Bargaining Power of Buyers
    3. 3.2.2.3 Threat of New Entrants
    4. 3.2.2.4 Threat of Substitutes
    5. 3.2.2.5 Intensity of Rivalry
  3. 3.2.3 COVID-19 Impact Analysis
    1. 3.2.3.1 Market Impact Analysis
    2. 3.2.3.2 Regional Impact
    3. 3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
1. 4.1 Healthcare, BY Disease Stage (USD Million)
  1. 4.1.1 Early Stage
  2. 4.1.2 Intermediate Stage
  3. 4.1.3 Late Stage
2. 4.2 Healthcare, BY Treatment Type (USD Million)
  1. 4.2.1 Pharmacological Treatment
  2. 4.2.2 Surgical Intervention
  3. 4.2.3 Nutritional Supplements
3. 4.3 Healthcare, BY Patient Demographics (USD Million)
  1. 4.3.1 Age Group
  2. 4.3.2 Gender
  3. 4.3.3 Socioeconomic Status
4. 4.4 Healthcare, BY Healthcare Setting (USD Million)
  1. 4.4.1 Outpatient Clinics
  2. 4.4.2 Hospitals
  3. 4.4.3 Home Healthcare
5. 4.5 Healthcare, BY Market Distribution Channel (USD Million)
  1. 4.5.1 Direct Sales
  2. 4.5.2 Online Sales
  3. 4.5.3 Pharmacies
5 SECTION V: COMPETITIVE ANALYSIS
1. 5.1 Competitive Landscape
  1. 5.1.1 Overview
  2. 5.1.2 Competitive Analysis
  3. 5.1.3 Market share Analysis
  4. 5.1.4 Major Growth Strategy in the Healthcare
  5. 5.1.5 Competitive Benchmarking
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare
  7. 5.1.7 Key developments and growth strategies
    1. 5.1.7.1 New Product Launch/Service Deployment
    2. 5.1.7.2 Merger & Acquisitions
    3. 5.1.7.3 Joint Ventures
  8. 5.1.8 Major Players Financial Matrix
    1. 5.1.8.1 Sales and Operating Income
    2. 5.1.8.2 Major Players R&D Expenditure. 2023
2. 5.2 Company Profiles
  1. 5.2.1 Novartis AG (CH)
    1. 5.2.1.1 Financial Overview
    2. 5.2.1.2 Products Offered
    3. 5.2.1.3 Key Developments
    4. 5.2.1.4 SWOT Analysis
    5. 5.2.1.5 Key Strategies
  2. 5.2.2 Regeneron Pharmaceuticals Inc (US)
    1. 5.2.2.1 Financial Overview
    2. 5.2.2.2 Products Offered
    3. 5.2.2.3 Key Developments
    4. 5.2.2.4 SWOT Analysis
    5. 5.2.2.5 Key Strategies
  3. 5.2.3 Roche Holding AG (CH)
    1. 5.2.3.1 Financial Overview
    2. 5.2.3.2 Products Offered
    3. 5.2.3.3 Key Developments
    4. 5.2.3.4 SWOT Analysis
    5. 5.2.3.5 Key Strategies
  4. 5.2.4 Bayer AG (DE)
    1. 5.2.4.1 Financial Overview
    2. 5.2.4.2 Products Offered
    3. 5.2.4.3 Key Developments
    4. 5.2.4.4 SWOT Analysis
    5. 5.2.4.5 Key Strategies
  5. 5.2.5 Allergan PLC (IE)
    1. 5.2.5.1 Financial Overview
    2. 5.2.5.2 Products Offered
    3. 5.2.5.3 Key Developments
    4. 5.2.5.4 SWOT Analysis
    5. 5.2.5.5 Key Strategies
  6. 5.2.6 Apellis Pharmaceuticals Inc (US)
    1. 5.2.6.1 Financial Overview
    2. 5.2.6.2 Products Offered
    3. 5.2.6.3 Key Developments
    4. 5.2.6.4 SWOT Analysis
    5. 5.2.6.5 Key Strategies
  7. 5.2.7 Santen Pharmaceutical Co Ltd (JP)
    1. 5.2.7.1 Financial Overview
    2. 5.2.7.2 Products Offered
    3. 5.2.7.3 Key Developments
    4. 5.2.7.4 SWOT Analysis
    5. 5.2.7.5 Key Strategies
  8. 5.2.8 Zeiss Group (DE)
    1. 5.2.8.1 Financial Overview
    2. 5.2.8.2 Products Offered
    3. 5.2.8.3 Key Developments
    4. 5.2.8.4 SWOT Analysis
    5. 5.2.8.5 Key Strategies
3. 5.3 Appendix
  1. 5.3.1 References
  2. 5.3.2 Related Reports
6 LIST OF FIGURES
1. 6.1 MARKET SYNOPSIS
2. 6.2 UK MARKET ANALYSIS BY DISEASE STAGE
3. 6.3 UK MARKET ANALYSIS BY TREATMENT TYPE
4. 6.4 UK MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
5. 6.5 UK MARKET ANALYSIS BY HEALTHCARE SETTING
6. 6.6 UK MARKET ANALYSIS BY MARKET DISTRIBUTION CHANNEL
7. 6.7 KEY BUYING CRITERIA OF HEALTHCARE
8. 6.8 RESEARCH PROCESS OF MRFR
9. 6.9 DRO ANALYSIS OF HEALTHCARE
10. 6.10 DRIVERS IMPACT ANALYSIS: HEALTHCARE
11. 6.11 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE
12. 6.12 SUPPLY / VALUE CHAIN: HEALTHCARE
13. 6.13 HEALTHCARE, BY DISEASE STAGE, 2024 (% SHARE)
14. 6.14 HEALTHCARE, BY DISEASE STAGE, 2024 TO 2035 (USD Million)
15. 6.15 HEALTHCARE, BY TREATMENT TYPE, 2024 (% SHARE)
16. 6.16 HEALTHCARE, BY TREATMENT TYPE, 2024 TO 2035 (USD Million)
17. 6.17 HEALTHCARE, BY PATIENT DEMOGRAPHICS, 2024 (% SHARE)
18. 6.18 HEALTHCARE, BY PATIENT DEMOGRAPHICS, 2024 TO 2035 (USD Million)
19. 6.19 HEALTHCARE, BY HEALTHCARE SETTING, 2024 (% SHARE)
20. 6.20 HEALTHCARE, BY HEALTHCARE SETTING, 2024 TO 2035 (USD Million)
21. 6.21 HEALTHCARE, BY MARKET DISTRIBUTION CHANNEL, 2024 (% SHARE)
22. 6.22 HEALTHCARE, BY MARKET DISTRIBUTION CHANNEL, 2024 TO 2035 (USD Million)
23. 6.23 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
1. 7.1 LIST OF ASSUMPTIONS
7.1.1
1. 7.2 UK MARKET SIZE ESTIMATES; FORECAST
  1. 7.2.1 BY DISEASE STAGE, 2026-2035 (USD Million)
  2. 7.2.2 BY TREATMENT TYPE, 2026-2035 (USD Million)
  3. 7.2.3 BY PATIENT DEMOGRAPHICS, 2026-2035 (USD Million)
  4. 7.2.4 BY HEALTHCARE SETTING, 2026-2035 (USD Million)
  5. 7.2.5 BY MARKET DISTRIBUTION CHANNEL, 2026-2035 (USD Million)
2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.3.1
1. 7.4 ACQUISITION/PARTNERSHIP
7.4.1

Certified Researchers

Customize Report

UK Healthcare Market Segmentation

Healthcare By Disease Stage (USD Million, 2026-2035)

Early Stage
Intermediate Stage
Late Stage

Healthcare By Treatment Type (USD Million, 2026-2035)

Pharmacological Treatment
Surgical Intervention
Nutritional Supplements

Healthcare By Patient Demographics (USD Million, 2026-2035)

Age Group
Gender
Socioeconomic Status

Healthcare By Healthcare Setting (USD Million, 2026-2035)

Outpatient Clinics
Hospitals
Home Healthcare

Healthcare By Market Distribution Channel (USD Million, 2026-2035)

Direct Sales
Online Sales
Pharmacies

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”